KCNA3 and plasma cell myeloma: The Kv1.3 inhibitors PAPTP and PCARBTP are efficient against both tested human multiple myeloma cell lines and against ex vivo-cultured, patient-derived myeloma cells, while healthy bone marrow cells are spared from toxicity.